Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemiaMonika Brüggemann, Michael Kneba, Heinz‐August Horst et al.|Blood|2005Cited by 537
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disordersMarco Ladetto, Christiane Pott, Monika Brüggemann et al.|Leukemia|2013Cited by 305
Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCRMatthias Ritgen, Peter Dreger, Stephan Stilgenbauer et al.|Blood|2004Cited by 170
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphomaChristiane Pott, Michael Kneba, Carsten Schrader et al.|Blood|2005Cited by 162
Detecting measurable residual disease beyond 10−4 by an IGHV leader-based NGS approach improves prognostic stratification in CLLPaul J. Hengeveld, Anton W. Langerak, Michèle Y. van der Klift et al.|Blood|2022Cited by 24